Online inquiry

IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14058MR)

This product GTTS-WQ14058MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14058MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13999MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ15662MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ15104MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ12875MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ10285MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ6558MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ10494MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ11643MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGD-013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW